SE9003025L - Tumoermarkoerer - Google Patents

Tumoermarkoerer

Info

Publication number
SE9003025L
SE9003025L SE9003025A SE9003025A SE9003025L SE 9003025 L SE9003025 L SE 9003025L SE 9003025 A SE9003025 A SE 9003025A SE 9003025 A SE9003025 A SE 9003025A SE 9003025 L SE9003025 L SE 9003025L
Authority
SE
Sweden
Prior art keywords
pct
fragments
cytokeratins
antibodies
sec
Prior art date
Application number
SE9003025A
Other languages
Unknown language ( )
English (en)
Other versions
SE470273B (sv
SE9003025D0 (sv
Inventor
Aake Silen
Bo Wiklund
Original Assignee
Aake Silen
Bo Wiklund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aake Silen, Bo Wiklund filed Critical Aake Silen
Priority to SE9003025A priority Critical patent/SE470273B/sv
Publication of SE9003025D0 publication Critical patent/SE9003025D0/sv
Priority to DE69132122T priority patent/DE69132122T2/de
Priority to AT91917180T priority patent/ATE191921T1/de
Priority to EP91917180A priority patent/EP0550561B1/en
Priority to PCT/SE1991/000638 priority patent/WO1992005197A1/en
Priority to JP51612591A priority patent/JP3210666B2/ja
Priority to AU85463/91A priority patent/AU8546391A/en
Priority to US08/030,100 priority patent/US5728537A/en
Publication of SE9003025L publication Critical patent/SE9003025L/sv
Publication of SE470273B publication Critical patent/SE470273B/sv
Priority to US08/666,835 priority patent/US5780032A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE9003025A 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer SE470273B (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
US08/030,100 US5728537A (en) 1990-09-24 1991-09-24 Methods of producing antibodies against cytokeraton fragments and test kits containing such fragments
PCT/SE1991/000638 WO1992005197A1 (en) 1990-09-24 1991-09-24 Purification of cytokeratin fragments
AT91917180T ATE191921T1 (de) 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten
EP91917180A EP0550561B1 (en) 1990-09-24 1991-09-24 Purification of cytokeratin fragments
DE69132122T DE69132122T2 (de) 1990-09-24 1991-09-24 Reinigung von cytokeratinfragmenten
JP51612591A JP3210666B2 (ja) 1990-09-24 1991-09-24 サイトケラチン断片の精製
AU85463/91A AU8546391A (en) 1990-09-24 1991-09-24 Purification of cytokeratin fragments
US08/666,835 US5780032A (en) 1990-09-24 1996-06-19 Method of using monoclonal antibodies to cytokeratin fragments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer

Publications (3)

Publication Number Publication Date
SE9003025D0 SE9003025D0 (sv) 1990-09-24
SE9003025L true SE9003025L (sv) 1992-03-25
SE470273B SE470273B (sv) 1993-12-20

Family

ID=20380430

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9003025A SE470273B (sv) 1990-09-24 1990-09-24 Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer

Country Status (8)

Country Link
US (2) US5728537A (sv)
EP (1) EP0550561B1 (sv)
JP (1) JP3210666B2 (sv)
AT (1) ATE191921T1 (sv)
AU (1) AU8546391A (sv)
DE (1) DE69132122T2 (sv)
SE (1) SE470273B (sv)
WO (1) WO1992005197A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
ES2116906B1 (es) * 1996-03-28 1999-03-01 Consejo Superior Investigacion Anticuerpo monocional pc2.27 asociado a tumores.
US6890311B2 (en) 1997-09-16 2005-05-10 The Regents Of The University Of California Methods for performing medical procedures within a breast duct
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
DE69840509D1 (de) 1997-09-30 2009-03-12 Peviva Ab Apoptose-bezogene verbindungen und deren verwendung
DE50015293D1 (de) * 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
JP2005500812A (ja) * 2000-12-21 2005-01-13 ジェンザイム・コーポレーション 治療および診断のための抗原性ｃｋ−１８化合物ならびにその使用方法
DE10130985B4 (de) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
EP1461001A4 (en) * 2002-01-03 2010-03-31 Scripps Research Inst EPITOPE ASSOCIATED WITH CANCER
EP1698899A4 (en) * 2003-10-30 2007-05-23 Sysmex Corp UTERINE GLAND CANCER DIAGNOSIS AND METHOD FOR DETECTION OF CANCER CELLS OF UTERINE GLAND
CN101583722A (zh) * 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
KR101292163B1 (ko) 2010-11-23 2013-08-12 한양대학교 산학협력단 Ｋｒｔ１９ 항체를 포함하는 항암용 조성물
SE538211C2 (sv) * 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167616B1 (en) * 1984-01-06 1995-07-26 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
US4727021A (en) * 1984-06-01 1988-02-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cytokeratin
US4722895A (en) * 1984-09-25 1988-02-02 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Synthetic peptides for the production of specific keratin protein antibodies
LU86654A1 (de) * 1986-11-10 1988-06-13 Progen Biotechnik Gmbh Verfahren und vorrichtung zum auffinden von zellaesionen
EP0267355B1 (de) * 1986-11-10 1991-09-18 PROGEN Biotechnik GmbH Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine
DE3815932A1 (de) * 1988-01-26 1989-08-03 Progen Biotechnik Gmbh Verfahren zur identifizierung des ursprungs einer zellgewebsprobe
CA2131528C (en) * 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors

Also Published As

Publication number Publication date
SE470273B (sv) 1993-12-20
JP3210666B2 (ja) 2001-09-17
ATE191921T1 (de) 2000-05-15
DE69132122D1 (de) 2000-05-25
EP0550561A1 (en) 1993-07-14
AU8546391A (en) 1992-04-15
JPH06501469A (ja) 1994-02-17
SE9003025D0 (sv) 1990-09-24
WO1992005197A1 (en) 1992-04-02
US5728537A (en) 1998-03-17
US5780032A (en) 1998-07-14
DE69132122T2 (de) 2001-01-11
EP0550561B1 (en) 2000-04-19

Similar Documents

Publication Publication Date Title
SE9003025L (sv) Tumoermarkoerer
EP0741868A1 (en) Immunoassays for prostate specific antigen
GB2128630A (en) Method of affinity purification employing monoclonal antibodies
CA2047717A1 (en) Monoclonal antibodies for small moieties, methods therefor
FI950378A0 (sv) Immuntest för detektering av kollagen eller kollagenfragmenter
FI922017A (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
ATE128986T1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
ATE151882T1 (de) Karzinomverwandtes haptoglobin (hpr)
DE69015230T2 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
IL69997A0 (en) Procainamide and n-acetylprocainamide immunogens,antibodies prepared therefrom,labeled conjugates,and the use of such antibodies and labeled conjugates in immunoassays
DE59010723D1 (de) Verwendung kohlenwasserstoffreicher Gele als Fracturing-Flüssigkeiten
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
DE69111429T2 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
IL68364A0 (en) Ethosuximide immunogens,antibodies prepared therefrom,labeled ethosuximide conjugates and related derivatives and the use of such antibodies and labeled conjugates in immunoassays
CA2178504A1 (en) Immunoassays for prostate specific antigen
ES477409A1 (es) Un metodo para la fabricacion de lentes de contacto blandas.
DE3990097T1 (de) Immunoassays unter verwendung monoklonaler antikoerper, die gegen natuerliche bindende proteine gerichtet sind
DK182188A (da) Humant tumorassocieret antigen
GR890100333A (en) Antihuman antigen antibodies

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 9003025-5

Format of ref document f/p: F

NUG Patent has lapsed